The company uses bioinformatics to analyze transcription data from human disease and identify new approaches to target key compartments of the immune system. Abcuro is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to treat inclusion body myositis (IBM), and has received FDA orphan drug designation for it. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.